SAFC Expands PharmaGrade Raw Materials Portfolio to Meet Growing Demand; Expects to Double PharmaGrade Portfolio in 2013

   SAFC Expands PharmaGrade Raw Materials Portfolio to Meet Growing Demand;
               Expects to Double PharmaGrade Portfolio in 2013

PR Newswire

ST. LOUIS, March 5, 2013

ST. LOUIS, March 5, 2013 /PRNewswire/ -- Sigma-Aldrich Corporation (NASDAQ:
SIAL) today announced that its custom manufacturing and services business
unit, SAFC (, is expanding its line of PharmaGrade products
with the addition of 20 raw materials for biopharmaceutical manufacturing. The
PharmaGrade portfolio of high quality buffers, amino acids and specialty
chemicals is expected to double in size by the end of 2013.

As the premier product line within SAFC's critical raw material offering,
PharmaGrade addresses the need for greater supply chain transparency and
enhanced quality for biopharmaceutical manufacturing applications. Products in
the PharmaGrade portfolio are provided with full documentation of
manufacturing history, are compliant with either GMP (Good Manufacturing
Practice) standards or the SAFC Elite Quality grade standards, and are quality
assurance reviewed and released. PharmaGrade products also include applicable
change control notification and a dedicated product support team.

Since its launch in early 2012, the PharmaGrade program began with more than
30 products and has continued to steadily grow. Sigma-Aldrich's acquisition of
Research Organics, Inc. in April 2012 contributed significantly to the
program's resources and capabilities to further support the increasing market
demand for new PharmaGrade materials. SAFC expects the PharmaGrade portfolio
to grow to 80 raw materials with the addition of 20 new products available at
the end of March 2013.

"The introduction of the PharmaGrade portfolio was designed to meet the
growing need for greater transparency for raw materials. The initiative has
been extremely well received by our customers and has resulted in tremendous
demand for the portfolio," stated Deb Slagle, Vice President of Marketing and
Research Development at SAFC. "The acquisition of Research Organics has
accelerated our ability to add products more rapidly and significantly
contributed to the overall success of the portfolio."

"PharmaGrade is a clear reflection of our drive to offer quality products in
tandem with exceptional customer support," added Gilles Cottier, President of
SAFC. "We felt that by listening to our customers and offering a level of
products they need with the support they need, we would be able to enhance the
quality of solutions we can offer to the market. We continue to apply all
feedback to the further development of the line, and will continue to expand
the PharmaGrade portfolio in a strategic manner."

For more information on the PharmaGrade portfolio and its complete listing of

The foregoing release contains forward-looking statements that can be
identified by terminology such as "is expected to" or similar expressions, or
by expressed or implied discussions regarding potential future revenues from
products derived there from. You should not place undue reliance on these
statements. There can be no guarantee that the products in SAFC's product
offering will continue to meet the demands of the marketplace. Nor can there
be any guarantee that any of these products will achieve any particular levels
of revenue in the future. Such forward-looking statements reflect the current
views of management regarding future events, and involve known and unknown
risks, uncertainties and other factors that may cause actual results to be
materially different from any future results, performance or achievements
expressed or implied by such statements. In particular, management's
expectations regarding these products could be affected by, among other
things, unexpected regulatory actions or delays or government regulation
generally; the Company's ability to obtain or maintain patent or other
proprietary intellectual property protection; competition in general;
government, industry and general public pricing pressures; the impact that the
foregoing factors could have on the values attributed to the Company's assets
and liabilities as recorded in its consolidated balance sheet, and other risks
and factors referred to in Sigma-Aldrich's current Form 10-K on file with the
US Securities and Exchange Commission. Should one or more of these risks or
uncertainties materialize, or should underlying assumptions prove incorrect,
actual results may vary materially from those anticipated, believed, estimated
or expected. Sigma-Aldrich is providing the information in this press release
as of this date and does not undertake any obligation to update any
forward-looking statements contained in this press release as a result of new
information, future events or otherwise.

About SAFC: SAFC, the custom manufacturing and services business unit of
Sigma-Aldrich Corporation, is recognized as a top 10 global specialty
chemicals and biologics supplier. As a trusted manufacturer for the life
science and high technology industries, SAFC works closely with customers to
resolve development challenges and accelerate the product pipeline utilizing
its global "Centers of Excellence" and dedicated manufacturing facilities. Its
rich portfolio includes high-purity inorganic materials for high technology
applications, critical raw materials and extensive biologics safety testing
services for biopharmaceutical manufacturing, and complex, high-potent APIs
and key intermediates for pharmaceutical manufacturing. For more information,

About Sigma-Aldrich: Sigma-Aldrich is a leading Life Science and High
Technology company whose biochemical, organic chemical products, kits and
services are used in scientific research, including genomic and proteomic
research, biotechnology, pharmaceutical development, the diagnosis of disease
and as key components in pharmaceutical, diagnostics and high technology SAFC
manufacturing. Sigma-Aldrich customers include more than 1.3 million
scientists and technologists in life science companies, university and
government institutions, hospitals and industry. The Company operates in 38
countries and has nearly 9,000 employees whose objective is to provide
excellent service worldwide. Sigma-Aldrich is committed to accelerating
customer success through innovation and leadership in Life Science and High
Technology. For more information about Sigma-Aldrich, please visit its website

©2013 Sigma-Aldrich Co. LLC. All rights reserved. Sigma-Aldrich and SAFC are
trademarks of Sigma-Aldrich Co. LLC or its Affiliates, registered in the US
and other countries.

SOURCE Sigma-Aldrich Corporation

Contact: SAFC Inquiries, Kristi Fortschneider, Marketing Communications
Coordinator, +1-314-286-8331 x2407, or Media Inquiries, Beth Willers, Impress
Labs +1-503)-928-7828,
Press spacebar to pause and continue. Press esc to stop.